Şenoğlu, YusufTaşkıran, Arda TaşkınYüksel, AlpaslanBaba, Dursun2023-07-262023-07-2620222147-2270https://doi.org/10.4274/uob.galenos.2021.2021.4.1https://hdl.handle.net/20.500.12684/12748Objective: Our aim was to compare the diagnostic efficacy of the standard systematic, targeted and combined prostate biopsy methods in prostate cancer. Materials and Methods: Total of 161 patients who underwent prostate biopsy combined with magnetic resonance imaging-ultrasonography fusion method between August 2018 and March 2021 was evaluated retrospectively. Clinically important and insignificant cancer detection rates of biopsy results between standard, targeted and combined biopsy (CB) methods were compared. Changes in the results were also evaluated in terms of Prostate Imaging-Reporting and Data System (PIRADS) scores. Results: Prostate cancer was diagnosed in 46 (28.6%) patients by CB. Fourteen (8.7%) patients were interpreted as a clinically insignificant disease. Prostate cancer and clinically significant disease detection rates were statistically significant in favor of CB compared to targeted biopsy (TB). There was no statistically significant difference between systematic biopsy and TB results. Additionally, it was observed that cancer detection rates were higher in PIRADS o4 lesions compared to PIRADS 3 lesions in all biopsy methods. Conclusions: Our results have shown that combined prostate biopsy led to higher detection of prostate cancer and provides increased detection of clinically significant disease. High rates of clinically significant cancer, especially in patients with PIRADS o4 lesions, suggest that the PIRADS scoring is a high-level guide in detecting malignancy.en10.4274/uob.galenos.2021.2021.4.1info:eu-repo/semantics/openAccessProstate Cancer; Clinical Significance; Targeted Biopsy; Mri Us Fusion; Combined BiopsyMagnetic-Resonance; Saturation Biopsy; Cancer Detection; Fusion Biopsy; Diagnosis; MriArticle2124044WOS:000806738500002N/A